Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)–Added trial

This publication has 11 references indexed in Scilit:

• The Benefits of Early Combination Treatment of Carvedilol and an ACE-Inhibitor in Mild Heart Failure and Left Ventricular Systolic Dysfunction. The Carvedilol and ACE-Inhibitor Remodelling Mild Heart Failure Evaluation Trial (CARMEN)
  Cardiovascular Drugs and Therapy, 2004
• Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
  The Lancet, 2003
• Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure
  Circulation, 2002
• Outcome of patients with congestive heart failure treated with standard versus high doses of enalapril: a multicenter study
  Journal of the American College of Cardiology, 2000
• Rationale for the use of combination angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker therapy in heart failure
  American Heart Journal, 2000
• Effects of Controlled-Release Metoprolol on Total Mortality, Hospitalizations, and Well-being in Patients With Heart Failure
  JAMA, 2000
• The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure
  New England Journal of Medicine, 1999
• A Comparison of Enalapril with Hydralazine–Isosorbide Dinitrate in the Treatment of Chronic Congestive Heart Failure
  New England Journal of Medicine, 1991
• Effect of Enalapril on Survival in Patients with Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure
  New England Journal of Medicine, 1991
• Effects of Enalapril on Mortality in Severe Congestive Heart Failure
  New England Journal of Medicine, 1987